A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Phase 2 Completed
57 enrolled 14 charts
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Phase 2 Completed
57 enrolled 18 charts
A Study of Nivolumab in Selected Uterine Cancer Patients
Phase 2 Completed
35 enrolled 8 charts
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
73 enrolled 11 charts
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Phase 2 Completed
17 enrolled
M6620 (VX-970) in Selected Solid Tumors
Phase 2 Completed
30 enrolled 15 charts
TRAVELL
Phase 2 Completed
105 enrolled
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Phase 2 Completed
54 enrolled 12 charts
LMS03
Phase 2 Completed
106 enrolled
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Phase 2 Completed
113 enrolled 13 charts
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
17 enrolled 9 charts
TAUL
Phase 2 Completed
168 enrolled
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase 2 Completed
72 enrolled 13 charts
Bevacizumab and Radiation Therapy for Sarcomas
Phase 2 Completed
20 enrolled 16 charts
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Phase 2 Completed
27 enrolled 4 charts
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2 Completed
185 enrolled
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
Phase 2 Completed
90 enrolled
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Phase 2 Completed
148 enrolled 8 charts
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Phase 2 Completed
47 enrolled 7 charts
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Phase 2 Completed
53 enrolled 6 charts
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Phase 2 Completed
37 enrolled 6 charts
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Phase 2 Completed
216 enrolled
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Phase 2 Completed
47 enrolled 16 charts
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Phase 2 Completed
53 enrolled
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Phase 2 Completed
271 enrolled 13 charts
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Phase 2 Completed
147 enrolled 13 charts
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Phase 2 Completed
51 enrolled 9 charts
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Phase 2 Completed
76 enrolled
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Phase 2 Completed
82 enrolled
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
132 enrolled
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Phase 2 Completed
48 enrolled 9 charts
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
39 enrolled
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
64 enrolled
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed